Characterization of bropirimineO-glucuronidation in human liver microsomes
- 1 October 2003
- journal article
- Published by Taylor & Francis in Xenobiotica
- Vol. 33 (10) , 999-1011
- https://doi.org/10.1080/00498250310001602757
Abstract
1. The antitumour agent bropirimine undergoes significant Phase II conjugation in vivo. Incubation of [14C]bropirimine with human liver microsomes resulted in the formation of a single product peak (M1) using high-performance liquid chromatography with radiochemical detection and was tentatively assigned as bropirimine glucuronide based on sensitivity to beta-glucuronidase and by obtaining the expected mass of 442/444 amu with liquid chromatography/mass spectrometry. Following metabolite isolation, the structure of M1 was established as bropirimine O-glucuronide by 1H-nuclear magnetic spectroscopy. 2. Studies aimed at identifying the human liver UDP-glucuronosyltransferase (UGT) enzyme(s) involved in the glucuronidation of bropirimine were carried out using recombinant human UGTs and it was determined that glucuronidation of bropirimine was catalysed by UGT1A1, UGT1A3 and UGT1A9. Bropirimine O-glucuronidation followed Michaelis-Menten kinetics and the Km and Vmax (mean +/- SD; n = 3) were 1217 +/- 205 microM and 667 +/- 188 pmol min(-1) mg(-1), respectively. 3. The activity of bropirimine O-glucuronidation by human liver microsomes was inhibited by bilirubin (40%) and with mefenamic acid (80%). Although buprenorphine extensively inhibited the activity of bropirimine O-glucuronidation by UGT1A3, the inhibition profile did not parallel that observed in HLMs. 4. The results demonstrate that UGT1A9 and to a lesser extent UGT1A1 are responsible for the majority of bropirimine O-glucuronidation in man.Keywords
This publication has 23 references indexed in Scilit:
- Quantitative Structure Activity Relationships for the Glucuronidation of Simple Phenols by Expressed Human UGT1A6 and UGT1A9Drug Metabolism and Disposition, 2002
- Characterization of Raloxifene Glucuronidation in Vitro: Contribution of Intestinal Metabolism to Presystemic ClearanceDrug Metabolism and Disposition, 2002
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- Oral communicationsAnnals of Oncology, 1998
- Drug Glucuronidation by Human Renal UDP-Glucuronosyltransferases 11The nomenclature used in this manuscript is based on published recommendations and is to be defined by the position of the variable exon within the gene complex [45]. The position of the specific isoform formerly known as HlugP4 or UGT1∗02 has yet to be resolved. As such, the nomenclature for this isoform will be stated as UGT1A8/9.Biochemical Pharmacology, 1998
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- The Glucuronidation of Exogenous and Endogenous Compounds by Stably Expressed Rat and Human UDP-Glucuronosyltransferase 1.1Archives of Biochemistry and Biophysics, 1996
- Gene Structure at the Human UGT1 Locus Creates Diversity in Isozyme Structure, Substrate Specificity, and RegulationProgress in Nucleic Acid Research and Molecular Biology, 1995
- Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase.Journal of Clinical Investigation, 1994
- The UDP Glucuronosyltransferase Gene Super family: Suggested Nomenclature Based on Evolutionary DivergenceDNA and Cell Biology, 1991